File Download
Supplementary
-
Citations:
- Appears in Collections:
postgraduate thesis: The effects of a methionine aminopepitdase inhibitor fumagillin on leukemia cell growth in-vitro
Title | The effects of a methionine aminopepitdase inhibitor fumagillin on leukemia cell growth in-vitro |
---|---|
Authors | |
Issue Date | 2013 |
Publisher | The University of Hong Kong (Pokfulam, Hong Kong) |
Citation | Mak, W. J. C. [麥允齡]. (2013). The effects of a methionine aminopepitdase inhibitor fumagillin on leukemia cell growth in-vitro. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091367 |
Abstract | Acute Myeloid Leukaemia (AML) is a disease normally found in elderly patients, with the median age of presentation at about 68 years. At this age, many of the patients are frail and unlikely to respond well to intensive chemotherapy treatments. Conventional chemotherapy eradicates the proliferating leukaemic progenitors while leaving the quiescent leukaemic stem cells undisturbed. These quiescent LSCs are able to then bring about leukaemic relapse. Fumagillin is a natural metabolite from Asperigillus fumigatus that is generally used as an anti-microbial agent but it is also known to bind to intracellular MetAP-II and inhibit endothelial cell growth. Many cancers are found to have an over expression of MetAP-II.
In the past, MetAP-II inhibitors have been tested and shown success in angiogenesis inhibition and tumor reduction. The aim of this study is to observe whether methionine aminopeptidase-2 inhibitors can be used in the treatment of acute myeloid leukemia. The investigation included a dose response comparison of various AML cell lines to fumagillin treatment, cell proliferation assay, a colony forming unit assay, and cell cycle analysis of KG-1 cells following three days of fumagillin treatment. I have determined that fumagillin does indeed decrease the cellular proliferation of KG-1 in vivo and at 10μM, prevents colony formation in methylcellulose plating. There is an increase in cells found in the sub-G1 phase with fumagillin treatment, as analyzed by flow cytometry. It is interpolated that fumagillin treatment increases AML cell apoptosis, in addition to hindering its ability to grow in culture. |
Degree | Master of Medical Sciences |
Subject | Acute myeloid leukemia - Treatment |
Dept/Program | Medicine |
Persistent Identifier | http://hdl.handle.net/10722/193534 |
HKU Library Item ID | b5091367 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, Wan-ling, Justina Crystaline | - |
dc.contributor.author | 麥允齡 | - |
dc.date.accessioned | 2014-01-13T23:10:35Z | - |
dc.date.available | 2014-01-13T23:10:35Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Mak, W. J. C. [麥允齡]. (2013). The effects of a methionine aminopepitdase inhibitor fumagillin on leukemia cell growth in-vitro. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091367 | - |
dc.identifier.uri | http://hdl.handle.net/10722/193534 | - |
dc.description.abstract | Acute Myeloid Leukaemia (AML) is a disease normally found in elderly patients, with the median age of presentation at about 68 years. At this age, many of the patients are frail and unlikely to respond well to intensive chemotherapy treatments. Conventional chemotherapy eradicates the proliferating leukaemic progenitors while leaving the quiescent leukaemic stem cells undisturbed. These quiescent LSCs are able to then bring about leukaemic relapse. Fumagillin is a natural metabolite from Asperigillus fumigatus that is generally used as an anti-microbial agent but it is also known to bind to intracellular MetAP-II and inhibit endothelial cell growth. Many cancers are found to have an over expression of MetAP-II. In the past, MetAP-II inhibitors have been tested and shown success in angiogenesis inhibition and tumor reduction. The aim of this study is to observe whether methionine aminopeptidase-2 inhibitors can be used in the treatment of acute myeloid leukemia. The investigation included a dose response comparison of various AML cell lines to fumagillin treatment, cell proliferation assay, a colony forming unit assay, and cell cycle analysis of KG-1 cells following three days of fumagillin treatment. I have determined that fumagillin does indeed decrease the cellular proliferation of KG-1 in vivo and at 10μM, prevents colony formation in methylcellulose plating. There is an increase in cells found in the sub-G1 phase with fumagillin treatment, as analyzed by flow cytometry. It is interpolated that fumagillin treatment increases AML cell apoptosis, in addition to hindering its ability to grow in culture. | - |
dc.language | eng | - |
dc.publisher | The University of Hong Kong (Pokfulam, Hong Kong) | - |
dc.relation.ispartof | HKU Theses Online (HKUTO) | - |
dc.rights | The author retains all proprietary rights, (such as patent rights) and the right to use in future works. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject.lcsh | Acute myeloid leukemia - Treatment | - |
dc.title | The effects of a methionine aminopepitdase inhibitor fumagillin on leukemia cell growth in-vitro | - |
dc.type | PG_Thesis | - |
dc.identifier.hkul | b5091367 | - |
dc.description.thesisname | Master of Medical Sciences | - |
dc.description.thesislevel | Master | - |
dc.description.thesisdiscipline | Medicine | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.5353/th_b5091367 | - |
dc.date.hkucongregation | 2013 | - |
dc.identifier.mmsid | 991035831739703414 | - |